Psychedelic medicines are approaching an inflection point. Molecules such as MDMA, psilocybin, LSD, DMT and 5-MeO-DMT have shown promise treating some of the most intractable disorders, including treatment-resistant depression (TRD) and post-traumatic stress disorder (PTSD). Positive late-stage data, increasing regulatory support, and growing pharmaceutical investment have shifted the conversation from whether psychedelic therapies have potential to what it will take for them to succeed in real-world use. Unlike conventional pharmaceuticals, these medicines combine a pharmacologic intervention with an intensive and highly personal treatment experience, creating complex questions around care delivery, long-term treatment, patient access, and equity.

Their success will depend not only on the efficacy of the molecules, but on how thoughtfully the surrounding experience of care is designed and delivered. Below, let’s explore five critical issues that will shape the path from clinical development to responsible, sustainable real-world use. In addition, we’ll identify key items that biopharma companies who are developing psychedelic therapies—or other organizations that are supporting the ecosystem of care delivery—need to consider to be successful.

1 – Stigma, Awareness, and the Narrative Challenge

The issue:

“Psychedelic” carries a complex cultural history, ranging from centuries of ceremonial and healing use of some psychedelic substances within Indigenous traditions, to associations with the 1960s counterculture, Schedule I classification, recreational use, and concerns about safety and abuse. At the same time, growing enthusiasm has created the opposite challenge: expectations among some patients, providers, and the public may run ahead of the evidence. Companies will need to establish psychedelic therapies as legitimate, evidence-based medical treatments while setting realistic expectations about who may benefit, what treatment involves, and what risks and limitations remain.

Why it matters now:

  • Provider awareness and skepticism – Many psychiatrists, primary care physicians (PCPs), and referral sources remain unfamiliar with the evidence, patient selection, safety profile, and practical realities of treatment.
  • Patient and caregiver education – Patients need clear, balanced information about safety, the treatment experience, expected outcomes, and how regulated medical treatment differs from recreational or non-medical use.
  • Managing hype and expectations – Companies must balance overcoming stigma with avoiding perceptions that psychedelics are universally effective, curative, or necessarily “one-and-done.”
  • Respecting the broader history – As psychedelics enter mainstream healthcare, companies should consider how they acknowledge Indigenous and traditional knowledge associated with some of these substances without appropriating or oversimplifying those traditions.
  • Federal vs. state-level usage – Decriminalization efforts and state-regulated programs may create confusion about how FDA-approved medical treatment differs from other forms of psychedelic access.

What companies need to figure out:

Companies need an evidence-based communications strategy that builds appropriate acceptance rather than simply awareness. They must determine which educational needs are product-specific versus category-wide and ensure that the emerging narrative is credible, appropriately calibrates expectations, respects the broader history of these medicines, and gives patients and providers the information needed to make informed treatment decisions.

2 – The Regulatory Environment: From Acceleration to Approval

The issue:

The FDA’s 2024 Complete Response Letter for Lykos Therapeutics’ MDMA-assisted therapy — issued despite two positive Phase III trials — raised fundamental questions about whether the agency’s existing frameworks could accommodate psychedelic-assisted therapy models. However, 2026 marked a significant shift in the federal government’s posture toward psychedelic medicines. The April Executive Order directed agencies to accelerate development and review, and the FDA subsequently awarded National Priority Vouchers to three psychedelic programs, finalized its psychedelic clinical-trial guidance in July, and scheduled a September public hearing on future therapeutic use. The direction of travel is increasingly supportive, but important questions remain around approval standards, rescheduling, risk evaluation and mitigation strategies (REMS), and the ultimate post-approval framework.

Why it matters now:

  • Approval and scheduling – Regulatory acceleration does not lower FDA’s approval standard, and Schedule I products will still require rescheduling following approval. Timing and ultimate scheduling remain important variables.
  • Clinical development standards – FDA’s final guidance provides greater clarity, but functional unblinding, expectancy bias, durability, the role of psychological support, abuse potential, and appropriate controls remain important considerations for clinical development.
  • International divergence – Regulatory pathways and controlled-substance frameworks differ internationally, requiring market-specific development and launch strategies.

What companies need to figure out:

Companies need to translate a more favorable policy environment into product-specific regulatory strategies while distinguishing regulatory acceleration from regulatory certainty. This means planning for different scheduling and REMS outcomes, engaging FDA early on unresolved questions, and designing care-delivery models that can adapt to eventual post-approval requirements while maintaining appropriate patient safeguards and access.

3 – Implementation and the Care Delivery Model

The issue:

A multi-hour, supervised psychedelic treatment session is unlike conventional pharmacotherapy and will require a fundamental redesign of the behavioral-health care pathway. Treatment is likely to involve screening and preparation, an extended administration and monitoring period, psychological support, and post-treatment follow-up or integration and will often require specialized care settings. This raises fundamental questions about who delivers each component of care, what training they require, where treatment occurs, and how the model can scale without compromising safety, quality, patient experience, or access.

Why it matters now:

  • Site of care and capacity – Session duration, room requirements, staffing, monitoring, and retreatment frequency will determine clinic capacity and operating requirements. They will also influence geographic access and whether treatment can extend beyond specialized centers in major metropolitan markets.
  • Consistency of care at scale – Clinical trials are delivered in highly controlled environments by specially trained investigators — a model that won’t scale directly to real-world practice. Companies must determine which elements of preparation, set and setting, human support, and follow-up are integral to safe, effective treatment and must be preserved, and which can be adapted for broader delivery without compromising outcomes.
  • Patient journey redesign – Psychedelic treatment introduces new steps into an already fragmented behavioral-health journey. Patients and providers will need support navigating screening, preparation, administration and follow-up, and companies must understand where patients may fall out of the pathway and who owns each transition between referring providers and treatment centers.

What companies need to figure out:

Companies must define and support a care-delivery model that preserves the elements necessary for safety, quality, and a positive patient experience while remaining practical and accessible at scale. This means making early decisions around treatment networks, provider roles and training, patient referrals, and post-treatment follow-up. It also requires translating a highly controlled clinical-trial model into a reproducible real-world model without unnecessary complexity or cost. Ultimately, the experience patients and providers have with the first approved products will do more to shape long-term confidence in the class than anything else, making it critical that early launches set realistic expectations and deliver on them.

4 – The Retreatment and Reimbursement Question

The issue:

Current clinical trials are designed around 1–2 administrations, but the real-world durability of effect and the need for redosing are poorly characterized. Every additional administration carries both financial cost and meaningful patient burden, including time, travel, preparation, and another intensive treatment experience. Without clarity on retreatment frequency, it is difficult to understand the long-term treatment experience or model its true cost. Additionally, payers will need evidence of durable outcomes, cost-effectiveness relative to existing treatments, and clear criteria for patient selection before approving these therapies.

Why it matters now:

  • The shift from chronic to intermittent treatment – For most patients, these treatments may not be “one and done,” but their potential benefit lies in shifting from a chronic treatment model to something more intermittent, whether through scheduled or as-needed maintenance.
  • Payer evidence requirements – Payers will want to see retreatment data or credible models of total cost of care before making coverage decisions.
  • Divergent retreatment strategies – Manufacturers are pursuing different strategies—including one- or two-dose induction, symptom-triggered retreatment, and planned maintenance—raising questions about treatment frequency, timing, durability, patient outcomes and burden, clinic capacity, and economics.

What companies need to figure out:

Companies must generate durability data and develop models that account for different induction and retreatment scenarios. They need to understand who needs another dose, what constitutes relapse, when retreatment should occur, how patients experience and value retreatment, whether subsequent administrations provide comparable benefit, and what the treatment trajectory looks like one, two, or five years after initiation.

5 – Big Pharma Entry and Raising the Bar for Strategic Value

The issue:

2025–2026 has seen significant acceleration in strategic investment and M&A across psychedelics, including Lilly’s partnership with AtaiBeckley, Otsuka’s acquisition of Transcend Therapeutics, and AbbVie’s acquisition of Gilgamesh’s lead program. These transactions signal that Big Pharma increasingly views psychedelics as a legitimate therapeutic category, but they also raise the bar for the next generation of companies.

Why it matters now:

  • Clinical validation vs. real-world viability – Positive Phase 3 data, growing regulatory support, and commercial success of SPRAVATO® have de-risked the category, but demonstrating efficacy is different from demonstrating that a treatment can work in real-world practice.  First indications will shape how the category is perceived by payers, providers, and the public. Companies should select beachheads that demonstrate meaningful impact in high-unmet-need populations, are operationally feasible in real-world care settings, and can withstand scrutiny if outcomes fall short of expectations.
  • Differentiation increasingly matters – Investors are evaluating not just molecular differentiation, but also treatment-model differentiation, which can include duration, durability and retreatment frequency, patient and site-of-care burden, safety, IP, and indication breadth.
  • Commercial readiness as a value driver – Companies that can articulate a credible path from approval to reimbursed, accessible delivery—including site capacity, provider adoption and patient access—may be better positioned to attract strategic interest. This dynamic may also favor acquirers with established CNS and behavioral health capabilities who can layer psychedelic therapies into existing infrastructure rather than building from scratch.

What companies need to figure out:

Increasingly, the diligence question is expanding beyond “Does the drug work ?”  to be “Can it become a differentiated therapy that patients can access, providers can deliver, payers can support, and the healthcare system can sustain?” Answering that requires credible thinking around durability and retreatment, care delivery, reimbursement, access, and competitive positioning. Companies that connect compelling clinical data to a credible, patient-centered model for real-world delivery will be best positioned to attract strategic partners and build sustainable long-term value.

Connective Thread: The Critical Role of Insights to Inform Strategy Development

Underpinning all five issues is a common challenge: there is no established playbook for bringing psychedelic therapies responsibly into healthcare. Companies are making consequential decisions around dosing and retreatment, care delivery, pricing and access, education, and launch strategy while the market itself is still taking shape- the proverbial building the plane while flying it. In addition to the obvious scientific considerations involved, those decisions require a significant amount of analysis and strategic thought in a complex and rapidly evolving environment. Therefore, they should be informed by insights derived directly from the individuals that will approve, pay for, and deliver these therapies, as well as from the patients who will experience them.

Gaining those insights is more complex than simply conducting more research. It requires being systematic about determining which uncertainties need to be resolved, whose perspectives are needed, and when those insights should be generated. This requires bringing together perspectives that are often considered separately, such as patients and caregivers, clinicians and treatment centers, payers and policymakers, and, where relevant, voices with lived, community, or traditional experience with psychedelic medicines.

  • Late-stage development – Understand the patient journey and treatment experience, provider attitudes and adoption barriers, emerging care-delivery models, and early payer perceptions of value.
  • Pre-approval – Pressure-test pricing and access assumptions, treatment-center capacity, workforce and training requirements, patient/referral pathways, and competitive positioning.
  • Peri-launch – Validate patient identification and referral strategies, optimize payer evidence, assess HCP readiness, and test patient and provider education and communications.
  • Post-launch – Track real-world retreatment and durability, patient and provider experience, access and uptake barriers, outcomes, and the evolving competitive landscape.

For psychedelic therapies, where the medicine, care-delivery model, patient experience, and market are all evolving simultaneously, systematic insights are essential. Companies that ask the right questions early—and listen to the full range of stakeholders affected by the answers—will be better equipped to build models of care that are clinically rigorous, commercially sustainable, accessible to patients, and respectful of what makes these therapies different.

Coming Next

This paper has examined five issues that biopharma and companies in the psychedelics space must navigate as they develop psychedelic therapy and delivery. However, each warrants far more attention than a single overview allows. In a forthcoming series, we will take up these issues in turn. For each, we’ll take a deep dive into the unique considerations and decisions innovators must navigate to chart an efficient path to market, drawing on perspectives from our work with multiple clients in the space.

To stay up to date on Blue Matter’s publications, please follow us on LinkedIn or check our Insights page regularly.

To contact the author, please send an email to jburgess@bluematterconsulting.com